PacBio rises on strong preliminary Q1 revenue, layoff plan
Shares of life science co PacBio PACB.O rise 8.8% to $1.30
Co reports preliminary Q1 revenue of $36.9 million vs analysts' average estimate of $33.5 million, according to data compiled by LSEG
Co plans to reduce its headcount and lower adjusted operating expense run-rate by $45 million to $50 million by year-end
"Given the persistent uncertainty surrounding academic and NIH funding, along with the introduction of new tariffs, we are taking strategic steps to reduce spending," CEO Christian Henry says
Up to last close, stock down 34.4% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Nebius Stock: Can This AI Infrastructure Play Really Double in 2026?

Amazon 2026 Q1 Earnings Preview: AWS and Advertising Dual Engines Power Ahead, Can They Allay Market Doubts?

Google Bets $40B on Anthropic: Is Google Cloud the New Growth Engine as Meta Challenges Ad Dominance?

Intel Posts Best Day Since 1987 as Nvidia Market Cap Reclaims $5 Trillion: Is the AI Trade Overstretched?

Citi Raises Brent Crude Forecast to $150: Strait of Hormuz Risks Brew, How High Can Oil Prices Rise?

Tradingkey







